New Platform Creates PhD-level Experts in Drug Development in Mere Days
New Platform Creates PhD-level Experts in Drug Development in Mere Days
PR Newswire
LONDON, Oct. 20, 2026
Inovia Bio's AI-powered "Falcon" cuts months of work from drug development to hours
LONDON, Oct. 20, 2026 /PRNewswire/ -- Inovia Bio, an AI company that accelerates drug development for pharmaceutical and lean biotech organizations, today announced the launch of Inovia Falcon Workflows (Falcon), an end-to-end AI system that completes advanced drug development work in hours. Inovia can now build new PhD-level AI employees in days, giving drug developers more expert capacity while their teams stay in charge of every decision.
"Drug development has never been short of good ideas. It is short of expert time," said Imi Faghmous, Co-Founder and Chief Development Officer of Inovia Bio. "Falcon takes on the heavy lifting, from forecasts to clinical study reports, so drug developers and regulatory leaders can spend their hours on the decisions only they can make. A human still reviews and signs off on every output."
Falcon completes the following drug development tasks:
- Drafting Clinical Study Protocols, Statistical Analysis Plans and Clinical Study Reports, built to industry standards within a validated, GCP-compliant workflow.
- Epidemiological and commercial forecasting
- Target Product Profile and Clinical Development Plan drafting
- Indication prioritization
- Competitive intelligence landscaping across clinical pipelines
- Systematic and targeted literature reviews
All work completed by the AI employees is reviewed and signed off by a human expert at appropriate steps.
"Our customers have relied on these individual workflows for two years," said Antonio Nicolae, Co-Founder and Chief Technology Officer of Inovia Bio. "The experts stay in charge. We just give them far more room to use their judgment on more pressing tasks."
Falcon's workflows are validated and built to comply with Good Clinical Practice (GCP), the international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials involving human participants. Over the past two years, every output of these workflows have undergone thousands of automated tests for both accuracy and safety.
About Inovia Bio:
Inovia Bio helps biotech and pharmaceutical organizations move therapies forward faster. Its AI platforms turn months of work into days, so experts spend their time on decisions, not drafts. Learn more at Inovia.Bio.
Media Contact:
Jeff Rusack
Sōvyn
inoviabio@sovyn.com
SOURCE Inovia Bio
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Are TIPS ETFs the Best Way to Fight Inflation?
10 Best Blue-Chip Stocks to Buy for the Long Term
United States